[go: up one dir, main page]

WO2022054068A1 - Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus - Google Patents

Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus Download PDF

Info

Publication number
WO2022054068A1
WO2022054068A1 PCT/IL2021/051128 IL2021051128W WO2022054068A1 WO 2022054068 A1 WO2022054068 A1 WO 2022054068A1 IL 2021051128 W IL2021051128 W IL 2021051128W WO 2022054068 A1 WO2022054068 A1 WO 2022054068A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
coronavirus
binding domain
antigen binding
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2021/051128
Other languages
English (en)
Inventor
Natalia FREUND
Michael MOR
David HAGIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Ichilov Tech Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Ichilov Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Ichilov Tech Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2022054068A1 publication Critical patent/WO2022054068A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Definitions

  • the present invention in some embodiments thereof, relates to antibodies for the prevention, treatment and detection of a Coronavirus infection.
  • Severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) is the etiological cause of the Coronavirus disease 19 (COVID-19) that emerged in late 2019, causing a global pandemic (7).
  • SARS CoV-2 belongs to the family Coronaviridae, alongside SARS-CoV that emerged in 2002 causing approximately 8,000 infections with a lethality of 10% (2).
  • These viruses, along with another closely related Middle East Respiratory Syndrome Coronavirus (MERS CoV), are the result of a zoonotic transfer from an animal reservoir that causes major lung damage and lifethreatening respiratory illness in humans (2). Presently, no approved targeted therapeutics are available for COVID- 19.
  • a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus for use in preventing or treating Coronavirus infection in a subject in need thereof, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a method of preventing or treating Coronavirus infection in a subject in need thereof comprising administering to the subject an effective amount of a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5, thereby preventing or treating Coronavirus in the subject.
  • CDRs complementarity determining regions
  • a method of producing an antibody capable of binding an antigenic determinant of Coronavirus comprising:
  • a vaccine comprising an effective amount of a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus and an excipient, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a monoclonal antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus and an excipient, wherein the antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus attached to a heterologous effector moiety or carrier, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • said antibody is a recombinant antibody.
  • said antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2212, 1109, 2230 or 2189.
  • said antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2212.
  • said antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2230.
  • said human antibody comprising an antigen binding domain which binds said Coronavirus comprises a plurality of different human antibodies each comprising an antigen binding domain which binds a Coronavirus.
  • said plurality of different human antibodies comprise: 1109, and 2212; 2303 and 1109; 2230 and 2212; 2189 and 2212; 1145 and 2212; and/or 2303 and 2212.
  • an antigen binding domain of said antibody comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • an antigen binding domain of said antibody comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2303 or 2310.
  • said antibody is labeled.
  • said contacting is effected in-vivo.
  • said contacting is effected ex- vivo.
  • a diagnostic kit for detecting a Coronavirus infection comprising a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus which allow a specific immunocomplex formation between said antibody and said Spike, wherein an antigen binding domain of said antibody comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • an antigen binding domain of said antibody comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2303 or 2310.
  • said antibody is labeled.
  • said human antibody comprising an antigen binding domain which binds said Coronavirus comprises a plurality of different human antibodies each comprising an antigen binding domain which binds a Coronavirus.
  • said Coronavirus is SAR-CoV-2, Middle East respiratory syndrome Coronavirus (MERS-CoV) or severe acute respiratory syndrome Coronavirus (SARS-CoV).
  • MERS-CoV Middle East respiratory syndrome Coronavirus
  • SARS-CoV severe acute respiratory syndrome Coronavirus
  • said Coronavirus is SAR-CoV-2.
  • FIGs. 1A-B show expression of SARS-CoV-2 receptor binding domain.
  • A schematic diagram of the RBD construct.
  • a human HGF signal peptide (SEQ ID NO: 179) was added at the N-terminal to enhance protein secretion.
  • two tags were added - a His-tag for protein purification and an Avi-tag for specific biotinylation.
  • B Representative western-blot of cell supernatant containing the RBD protein 3 days post transfection. The protein was detected via anti-Avitag antibody.
  • FIGs. 2A-I show serological responses towards SARS CoV-2 RBD.
  • Each patient plasma underwent 2-fold serial dilutions, incubated with the RBD protein and detected via (A) anti-human IgG (B) anti-human IgM or (C) anti-human IgA antibodies conjugated to HRP.
  • D Patient plasma was also tested for inhibition of RBD-ACE2 binding: ELISA plates were coated with human- ACE2 protein, while each patient plasma sample was pre-incubated with biotinylated RBD. The plasma-RBD mixture was then added to the plates and detected via strepavidin-HRP.
  • E-G Patient plasma inhibition data was plotted against plasma reactivity of IgG, IgM and IgA antibodies. Correlation and p-value were calculated by GraphPad Prism version 8.0.0.
  • FIGs. 3A-J show monoclonal antibodies cloned from donors CoVl and CoV2.
  • (a) Flow cytometry gating strategy for staining anti-SARS-CoV-2 RBD specific memory B cells
  • (b) Graph presents the frequencies of anti-SARS-CoV-2 RBD specific memory B cells in COVID-19 donors CoV01-CoV17. No PBMCs were obtained for donor C0VI8, therefore this donor was not included.
  • Symbol code is given on the right side of the panel
  • Pie charts represent the total number of RBD-specific memory B cell sequences (heavy chains) obtained from donors CoVOl and CoV02. The numbers in the middle of the pies represent the total number of sequences and the pink shaded slices represent B cell clonal families.
  • FIGs. 4A-D show activity of the 22 anti-SARS-CoV-2 mAbs in EFISA.
  • Antibodies were assayed at a starting concentration of 10 pg/ml with 7 additional consecutive 4- fold dilutions. The color-code is indicated to the right of each graph,
  • Antibodies were assayed at 300nM with 6 additional consecutive 4-fold dilutions. The y-axis is represented as log2 of the ODeso values. Lower OD indicates higher mAb inhibition, (d) Antibody competition with biotinylated-CR3022. Antibodies were pre-incubated with bound RBD before biotinylated- CR3022 was added and detected via streptavidin-HRP. Lower ODeso values indicate higher level of competition between the mAbs and CR3022.
  • FIGs. 5A-B predict the epitope of mAb TAU-2230 using phage-displayed affinity purified peptides
  • Fth-1 serves as a negative control phage that does not display an insert peptide.
  • the symbols corresponding to each peptide are shown in the right panel next to “Clone name”.
  • Right Panel amino acid sequences of 16 phage displayed affinity purified peptides. These peptides were used as input for the computer software “Mapitope”.
  • FIGs. 6A-F show neutralization by anti-SARS-CoV-2 mAbs.
  • Upper panel a table presenting IC50, IC80 and R squared for neutralization of Pseudo-typed GFP-reporter viral particles.
  • Lower panel pie chart presenting mAb classification based on ELISA mapping and pseudo-typed viral particle neutralization data. The number in the middle of the pie denotes the total number of mAbs tested and the slices represent neutralization. Color code is given below,
  • mAbs are shown along with “uninfected”, “no antibody”, and MGO.53, which serves as a human isotype mAb control, (c) quantification of (b).
  • FIGs. 7A-C show neutralizing activity by combinations of anti-SARS-CoV-2 mAbs targeting different sites, (a) monotreatment, (b) double mix (c) triple mix
  • FIG. 8 is a table representation of antibody binding affinity to each RBD generated in this study. Green color indicates binding affinity of >75%, orange of 25-75% and red of ⁇ 25% when compared to the wild type strain. The strain in which each mutation appears is indicated above the mutation. The antibodies are separated into ACE2bs and Non-ACE2bs mAbs.
  • FIGs. 9A-C show antibody binding to RBD of variants of concern (VOCs) compared to compared to wild type SARS-CoV-02 (W.T.). Binding was measured by ELISA for each mAb to (A) Alpha, Beta, Gamma and Delta VOCs, (B) single amino-acid mutations found in the VOC and other circulating strains and (C) double amino-acid mutations found in VOCs.
  • VOCs variants of concern
  • FIGs. 10A-C show inhibition of RBD:ACE2 interactions by the mAbs.
  • A Flow cytometry analysis of antibody interference to RBD:ACE2 binding. Antibodies were added to Spike expressing cells before adding ACE2 conjugated to APC. mGO53 antibody was used as negative control. Unlabeled ACE2 (“Cold” ACE2) was used a positive control for inhibition. Fluorescence was read using CytoFLEX S4 (Beckman Coulter).
  • B RBD:ACE2 inhibition potency by mAbs for each VOC Spike. Inhibition was calculated by the percent of ACE2 positive cells. Percentage of positive cells was normalized for each VOC and W.T.
  • C Pie charts indicating the percentage of antibodies with strong, mediocre or no inhibition for each VOC and W.T.
  • FIGs. 11A-B are graphs showing the affinity of antibodies of some embodiments of the invention summarized in a table, (a) SPR sensograms showing binding of injected SARS-CoV-2 RBD at six different concentrations (15.6 nM, 31.25 nM, 62.5 nM, 125 nM, 250 nM and 500 nM) to immobilized anti-SARS-CoV-2 TAU mAbs (0.5 pg/ml). mGO53 was used as isotype control. SPR assays were performed on a Biacore T200 instrument at 25 °C.
  • the present invention in some embodiments thereof, relates to antibodies for the prevention, treatment and detection of a Coronavirus infection.
  • mAbs TAU-1145, -2189, -2230 and -2303 are able to inhibit binding of RBD to human ACE2 while mAbs 1109, 1145, 1115, 2189, 2212, 2230, 2310 and 2303 neutralized live W.T. virus.
  • Some of the antibodies were also able to bind and neutralize variants of SARS-CoV-2.
  • the antibodies represent the most effective response of the human body towards the virus. Moreover, these are the safest antibodies to be used as drugs and passive vaccines. Combinations of antibodies can be used to overcome resistance and the ability to bind a conformational epitope in the case of 2212 is also promising in overcoming resistance which stems from mutations that affect linear epitopes. Indeed combinations of antibodies can lead to higher coverage against various variants of the virus.
  • these antibodies are also particularly effective as diagnostic tools. Usually neutralizing antibodies are targeting conserved sites on the virus, sites that have an important function during the viral life cycle and therefore substitutions due to random mutation in these epitopes are under negative selection pressure. In view of that, these antibodies can be used to detect different viral isolates.
  • the fact that embodiments of the invention describe several mAbs that bind to non-overlapping epitopes on the Spike protein, pairs of mAbs binding nonoverlapping sites can be used in a sandwich ELISA, or lateral flow assay the presence of SARS- CoV-2 and effectively detect it.
  • a monoclonal antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus and an excipient, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus attached to a heterologous effector moiety or carrier (e.g., protein, polymeric or lipid carrier, e.g., liposome), wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus for use in preventing or treating Coronavirus infection in a subject in need thereof, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • a method of preventing or treating Coronavirus infection in a subject in need thereof comprising administering to the subject an effective amount of a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5, thereby preventing or treating Coronavirus in the subject.
  • CDRs complementarity determining regions
  • a vaccine comprising an effective amount of a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus and an excipient, wherein said antigen binding domain comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • antigenic determinant refers to a peptidic amino acid sequence which comprises an epitope that is recognized by an antigen binding domain of an antibody. Hence the antigenic determinant may comprise one or more epitopes. According to a specific embodiment, the antigenic determinant forms a portion of a viral protein with or without amino acid alterations with respect to the wild-type viral sequence.
  • the antigenic determinant is of a Coronavirus.
  • the antibody comprises the CDRs of the respective antibodies as listed in Table 5, each of which is considered as a separate embodiment. Table 5 is considered as an integral part of this section of the document not limited to the Examples section only.
  • the antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2212, 1109, 2230 or 2189.
  • the antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2212.
  • the antigen binding domain comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2230.
  • Coronavirus refers to enveloped positive- stranded RNA viruses that belong to the family Coronaviridae and the order Nidovirales.
  • Corona viruses which are contemplated herein include, but are not limited to, 229E, NL63, OC43, and HKU1 with the first two classified as antigenic group 1 and the latter two belonging to group 2, typically leading to an upper respiratory tract infection manifested by common cold symptoms.
  • Coronaviruses which are zoonotic in origin, can evolve into a strain that can infect human beings leading to fatal illness.
  • SARS-CoV Middle East respiratory syndrome Coronavirus
  • SARS-CoV-2 Middle East respiratory syndrome Coronavirus
  • 2019-nCoV 2019-nCoV
  • the Corona virus is SARS-CoV-2.
  • the SARS-CoV-2 includes any variants and mutants thereof including, but not limited to, the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), P.l (Gamma), B.1.526 (Iota), B.1.427 (Epsilon), B.1.429 (Epsilon), B.1.617 (Kappa, Delta), B.1.525 (Eta) and P.2 (Zeta).
  • the present inventors have synthesized proteins of some of these variants, referred herein as “variants of concern” or “VOCs” to support the use of the antibodies or combinations thereof of some embodiments of the invention is combating wild type viruses and variants thereof.
  • antibody as used in this invention includes intact molecules as well as functional fragments thereof (such as Fab, F(ab')2, Fv, scFv, dsFv, or single domain molecules such as VH and VL) that are capable of binding to an epitope of an antigen, in this case PstSl.
  • the antibody is a whole or intact antibody. According to specific embodiments, the antibody is an antibody fragment.
  • Suitable antibody fragments for practicing some embodiments of the invention include a complementarity-determining region (CDR) of an immunoglobulin light chain (referred to herein as “light chain”), a complementarity-determining region of an immunoglobulin heavy chain (referred to herein as “heavy chain”), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, and antibody fragments comprising essentially whole variable regions of both light and heavy chains such as an Fv, a single chain Fv (scFv), a disulfide- stabilized Fv (dsFv), an Fab, an Fab’, and an F(ab’)2.
  • CDR complementarity-determining region
  • light chain referred to herein as “light chain”
  • heavy chain a complementarity-determining region of an immunoglobulin heavy chain
  • variable region of a light chain a variable region of a heavy chain
  • a light chain a variable region of a heavy
  • CDR complementarity-determining region
  • VH VH1 or Hl
  • CDRH2 or H2 CDRH3 or H3
  • CDRL1 or LI CDRL1 or LI
  • CDRL2 or L2 CDRL L3 or L3
  • the identity of the amino acid residues in a particular antibody that make up a variable region or a CDR can be determined using methods well known in the art and include methods such as sequence variability as defined by Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C.), location of the structural loop regions as defined by Chothia et al. (see, e.g., Chothia et al., Nature 342:877-883, 1989.), a compromise between Kabat and Chothia using Oxford Molecular's AbM antibody modeling software (now Accelrys®, see, Martin et al., 1989, Proc.
  • variable regions and CDRs may refer to variable regions and CDRs defined by any approach known in the art, including combinations of approaches.
  • Fv defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains;
  • scFv single chain Fv
  • dsFv disulfide- stabilized Fv
  • Fab a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and CHI domains thereof;
  • Fab a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule);
  • F(ab’)2 a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds); and
  • Single domain antibodies or nanobodies are composed of a single VH or VL domains which exhibit sufficient affinity to the antigen.
  • the antibody heavy chain constant region is chosen from, e.g., IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE.
  • the antibody is an IgG antibody.
  • the antibody isotype is IgGl or IgG4.
  • the antibody isotype is IgGl.
  • antibody type will depend on the immune effector function that the antibody is designed to elicit.
  • the antibody comprises an Fc domain.
  • the antibody is a naked antibody.
  • naked antibody refers to an antibody which does not comprise a heterologous effector moiety e.g. therapeutic moiety, detectable moiety.
  • heterologous means not occurring in nature in conjunction with the antibody.
  • the antibody comprises a heterologous effector moiety e.g. e.g. therapeutic moiety, detectable moiety.
  • the effector moiety can be proteinaceous or non- proteinaceous; the latter generally being generated using functional groups on the antibody and on the conjugate partner.
  • the effector moiety may be any molecule, including small molecule chemical compounds and polypeptides.
  • the effector moiety can be a known drug to Coronavirus infection.
  • the antibody is a monoclonal antibody.
  • Antibody fragments according to some embodiments of the invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
  • Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2.
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • a thiol reducing agent optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages
  • an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly.
  • cleaving antibodies such as separation of heavy chains to form monovalent lightheavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
  • Fv fragments comprise an association of VH and VE chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nafl Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or crosslinked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide.
  • sFv single-chain antigen binding proteins
  • the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
  • the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
  • Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97- 105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.
  • CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)]. It will be appreciated that for human therapy or diagnostics, humanized antibodies are preferably used.
  • the antibody is a humanized antibody.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigenbinding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • the antibody is a human antibody.
  • the human antibody carries human Vh,Dh, Jh, VI, J, gene segments such as in germ line antibodies or natural variants thereof.
  • synthetic antibodies are also contemplated.
  • Present teachings also provide for a method of producing an antibody capable of binding an antigenic determinant of Coronavirus, the method comprising:
  • a polynucleotide encoding an antibody of some embodiments of the invention is cloned into an expression construct selected according to the expression system used.
  • prokaryotic or eukaryotic cells can be used as host-expression systems to express the antibody of some embodiments of the invention.
  • host-expression systems include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the coding sequence; yeast transformed with recombinant yeast expression vectors containing the coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the coding sequence.
  • Mammalian expression systems can also be used to express the antibodies of some embodiments of the invention.
  • mammalian expression vectors include, but are not limited to, pcDNA3, pcDNA3. (+/-), pGL3, pZeoSV2(+/-), pSecTag2, pDisplay, pEF/myc/cyto, pCMV/myc/cyto, pCR3., pSinRep5, DH26S, DHBB, pNMT, pNMT4, pNMT8, which are available from Invitrogen, pCI which is available from Promega, pMbac, pPbac, pBK-RSV and pBK-CMV which are available from Strategene, pTRES which is available from Clontech, and their derivatives.
  • Expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses can be also used.
  • SV40 vectors include pSVT7 and pMT2.
  • Vectors derived from bovine papilloma virus include pBV-MTHA, and vectors derived from Epstein Bar virus include pHEBO, and p2O5.
  • exemplary vectors include pMSG, pAV009/A + , pMTO0/A + , pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV-40 early promoter, SV-40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
  • Examples of bacterial constructs include the pET series of E. coli expression vectors [Studier et al. (990) Methods in Enzymol. 85:60-89).
  • yeast a number of vectors containing constitutive or inducible promoters can be used, as disclosed in U.S. Pat. Application No: 5,932,447.
  • vectors can be used which promote integration of foreign DNA sequences into the yeast chromosome.
  • the expression of the coding sequence can be driven by a number of promoters.
  • viral promoters such as the 35S RNA and 9S RNA promoters of CaMV [Brisson et al. (984) Nature 30:5-54], or the coat protein promoter to TMV [Takamatsu et al. (987) EMBO J. 3:1] can be used.
  • plant promoters such as the small subunit of RUBISCO [Coruzzi et al. (984) EMBO J.
  • insects and mammalian host cell systems e.g., Expi293F cells (Thermo Fisher Scientific Inc.)
  • Expi293F cells Thermo Fisher Scientific Inc.
  • Other expression systems such as insects and mammalian host cell systems [(e.g., Expi293F cells (Thermo Fisher Scientific Inc.)], which are well known in the art and are further described hereinbelow can also be used by some embodiments of the invention.
  • antibodies can also be produced in in-vivo systems such as in mammals, e.g., goats, rabbits etc.
  • antibodies of some embodiments of the invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
  • standard protein purification techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.
  • the present teachings in embodiments thereof provide for a recombinant antibody, an antibody which is prepared by recombinant DNA technology. It defers from the isolated human antibody by the presence of non-naturally occurring sequences in the context of the isolated human antibody either at the DNA (e.g., promoter or other regulatory region) and/or protein level (e.g., Fc region, framework region). Once antibodies are obtained, they may be tested for activity.
  • DNA e.g., promoter or other regulatory region
  • protein level e.g., Fc region, framework region
  • antibodies described herein may be tested and/or characterized using a variety of methods. Such methods may be used to determine a variety of characteristics that may include, but are not limited to, antibody affinity; specificity; and activity (e.g., RBD binding, viral neutralization).
  • In vitro testing systems include but are not limited to Vero cells and lung organoids.
  • Antibody testing may further include testing in vivo (e.g., in animal and/or human studies) for one or more of toxicity (though in this case since the antibodies are of human origin they are considered safe), therapeutic effect, pharmacodynamics, pharmacokinetics, absorption, deposition, metabolism, and excretion. Testing in animals may include, but is not limited to, hampsters and Ace2-humanized mouse.
  • neutralize or “neutralizing” refers to an antibody that binds surface expressed viral Spike and inhibits its interaction with ACE2, as can be determined by an ELISA assay, e.g., whereby antibodies are added to Spike expressing cells before or after adding ACE2 conjugated to APCs.
  • Assays for determining binding of an antibody to a target antigen include, but are not limited to, ELISA and surface plasmon resonance (SPR).
  • binding refers to an antibody- antigen mode of binding, which is generally, in the range of KD below 500 nM, such as determined by ELISA.
  • the affinity of the antibody to its antigen is determined by Surface Plasmon Resonance (SPR).
  • KD refers to the equilibrium dissociation constant between the antigen binding domain and its respective antigen.
  • the KD for binding the target (e.g., SPIKE) is typically in the range of 0.01-100 nM
  • High binders which are specifically contemplated herein include, but are not limited to, 1109, 1115, 2303, 2310.
  • the antibody may be soluble or non- soluble.
  • the target may be soluble or non-soluble (i.e., particle/cell bound).
  • Non-soluble antibodies may be a part of a particle (synthetic or non-synthetic, e.g., liposome) or a cell (e.g., CAR-T cells, in which the antibody is part of a chimeric antigen receptor (CAR) typically as a scFv fragment).
  • CAR chimeric antigen receptor
  • Increasing the cytotoxic activity of an antibody where necessary can also be achieved such as by using an antibody-drug conjugate (ADC) concept.
  • ADC antibody-drug conjugate
  • the antibody is attached to a heterologous effector moiety that can be used to increase its toxicity or to render it detectable.
  • antibodies of the invention may be developed for antibody drug conjugate (ADC) therapeutic applications.
  • ADCs are antibodies in which one or more cargo (e.g., therapeutic agents) are attached [e.g. directly or via linker (e.g. a cleavable linker or a non- cleavable linker)].
  • ADCs are useful for delivery of therapeutic agents (e.g., drugs or cytotoxic agents, some are listed below under “combination therapy”) to one or more target cells or tissues (Panowski, S. et al., 204. mAbs 6:, 34-45).
  • ADCs may be designed to bind to a surface antigen on a targeted cell. Upon binding, the entire antibody- antigen complex may be internalized and directed to a cellular lysosome. ADCs may then be degraded, releasing the bound cargo.
  • polyclonal antibodies can be formulated as ADCs and as such are also envisaged herein.
  • the antibody-drug delivery system presents a robust candidate for the delivery of perspective COVID-19 therapeutics (Meta et al. Med Hypotheses. 2020 Nov; 144: 110254.).
  • Antibody-drug conjugates function by identifying the viral envelope proteins obligatory for the propagation of infection in healthy cells (in thie case Spike for instance).
  • HPAPI highly powerful active pharmaceutical ingredient
  • the subject can be treated or diagnosed with a plurality of antibodies to achieve maximal neutralization (inhibition of the virus) either as a treatment or as a vaccine. Also diagnosis may be benefited by the use of a plurality of antibodies.
  • plurality refers to at least 2 antibodies having different antibgen binding domains (at least one different CDR), e.g., 2-3, 2-4, 2-5, 2-6, 2-7. 2-9, 2-10, 3-4, 3-5, 3-6, 3-7. 3- 9, 3-10.
  • the plurality of antibodies bind different epitopes on the virus.
  • the plurality of antibodies are composed of an antibody that binds a linear epitope and an antibody that binds a conformational epitope.
  • the human antibody comprising an antigen binding domain which binds said Coronavirus comprises a plurality of different human antibodies each comprising an antigen binding domain which binds a Coronavirus.
  • the plurality of antibodies bind identical epitopes on the virus, but may be different in their effector (Fc-mediate) functions.
  • the human antibody comprising an antigen binding domain which binds said antigenic determinant comprises a plurality of different human antibodies each comprising an antigen binding domain which binds a Coronavirus.
  • the antibody binds the SPIKE protein of a Coronavirus.
  • receptor binding domain refers to the receptor (ACE2) binding domain of SARS-CoV-2 of SPIKE, residues Arg319-Phe541 of SPIKE (wild-type or mutant).
  • Binding can be qualified using various methods known in the art, such as ELISA (exemplified in the section which follows) and surface plasmon resonance (SPR).
  • ELISA exemplified in the section which follows
  • SPR surface plasmon resonance
  • the plurality of different human antibodies comprise: 1109, and 2212; 2303 and 1109; 2230 and 2212;
  • the present invention envisages immunization against-, and prevention or treatment of Coronavirus infection with any of the antibodies described herein.
  • treating refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology.
  • pathology disease, disorder or condition
  • Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.
  • the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
  • Prevention can be done by means of immunization, in this case passive immunization, where the antibody is administered.
  • the term “subject” includes mammals, preferably human beings, male or female, at any age or gender, which suffer from the pathology. Preferably, this term encompasses individuals who are at risk to develop the pathology (e.g., above 65 of age).
  • treating refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology.
  • pathology disease, disorder or condition
  • Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology (i.e., Coronavirus infection, e.g., COVID19 or related complications).
  • the term “preventing” refers to keeping a disease, disorder or condition (i.e., Coronavirus infection, e.g., COVID19 or related complications) from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
  • a disease, disorder or condition i.e., Coronavirus infection, e.g., COVID19 or related complications
  • Prevention can be done by means of immunization, in an embodiment passive immunization, where the antibody is administered, or active where the peptide is administered.
  • the term “subject” includes mammals, preferably human beings, male or female, at any age or gender, who suffer from the pathology. Preferably, this term encompasses individuals who are at risk to develop the pathology (e.g., above 60 or 65 of age) or exposed to the virus, e.g., healthcare personnel, education personnel etc.
  • composition of matter comprising the antibodies of the present invention can be administered to the subject per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
  • a "pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • active ingredient refers to the composition of matter comprising the antibodies accountable for the biological effect.
  • physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • An adjuvant is included under these phrases.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intrapulmonary or intraocular injections.
  • neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
  • molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport polypeptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB
  • pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers)
  • the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin polypeptide).
  • each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
  • compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer.
  • physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
  • Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
  • the compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continues infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
  • a suitable vehicle e.g., sterile, pyrogen-free water based solution
  • compositions of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (composition of matter comprising the antibodies) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., Coronaviral infection) or prolong the survival of the subject being treated. According to an embodiment of the present invention, an effective amount of the composition of matter comprising the antibodies of some embodiments of the present invention is an amount selected to neutralize Coronaviruses and/or eliminate infected cells e.g. by initiating ADCC.
  • a therapeutically effective amount means an amount of active ingredients (composition of matter comprising the antibodies) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., Coronaviral infection) or prolong the survival of the subject being treated.
  • an effective amount of the composition of matter comprising the antibodies of some embodiments of the present invention is an amount selected to neutralize Coronaviruses and/or eliminate infected cells
  • Coronavirus viral load any in vivo or in vitro method of evaluating Coronavirus viral load may be employed.
  • the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays.
  • a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals.
  • the data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage may vary depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 P-l).
  • Dosage amount and interval may be adjusted individually to provide the active ingredient at a sufficient amount to induce or suppress the biological effect (minimal effective concentration, MEC).
  • MEC minimum effective concentration
  • the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
  • dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
  • compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
  • compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
  • the present teachings further envisage treating with other anti-viral drugs or antiinflammatory drugs or anti-coagulants as separate treatments or in a co -formulation.
  • the antiviral drug is selected from the group consisting of remdesivir, an interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudin, cidofovir, fomivirsen, foscamet, ganciclovir, penciclovir, amantadine, rimantadine and zanamivir.
  • plasma treatments from infected persons who survived and/or antiHIV drugs such as lopinavir and ritonavir, as well as chloroquine.
  • the antibodies of some embodiments of the invention can be used to detect a Coronavirus and preferably used in diagnosis of Coronavirus infection.
  • an antigen binding domain of said antibody comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • an antigen binding domain of the antibody comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2303 or 2310.
  • the antibody is directly labeled to allow detection.
  • the antibody is indirectly labels such as by the use of a labels secondary antibody or by an Sandwich ELISA assay.
  • the contacting is effected in-vivo.
  • the contacting is effected ex-vivo.
  • kits for detecting a Coronavirus infection comprising a human antibody comprising an antigen binding domain which binds an antigenic determinant of Coronavirus which allow a specific immunocomplex formation between said antibody and said Spike, wherein an antigen binding domain of said antibody comprises the complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 or the heavy chain and light chain of an antibody selected from the group listed in Table 5.
  • CDRs complementarity determining regions
  • aantigen binding domain of said antibody comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of 2303 or 2310.
  • the human antibody comprising an antigen binding domain which binds said Coronavirus comprises a plurality of different human antibodies each comprising an antigen binding domain which binds a Coronavirus.
  • diagnosis refers to classifying a disease, determining a severity of a disease (grade or stage), monitoring progression, forecasting an outcome of the disease and/or prospects of recovery.
  • the subject may be a healthy subject (e.g., human) undergoing a routine well-being checkup.
  • the subject may be at risk of the disease or infection.
  • the method may be used to monitor treatment efficacy.
  • biological sample refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, sputum, and also samples of in vivo cell culture constituents. It should be noted that a “biological sample obtained from the subject” may also optionally comprise a sample that has not been physically removed from the subject (in vivo as opposed to in vitro).
  • tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of Coronaviruses or infected cells in the sample. Regardless of the procedure employed, once a biopsy/sample is obtained the level of the variant can be determined and a diagnosis can thus be made.
  • the method of the present invention is effected under conditions sufficient to form protein-protein interactions i.e., complex (e.g. a complex between).
  • complex e.g. a complex between
  • Such conditions e.g., appropriate concentrations, buffers, temperatures, reaction times
  • methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein below.
  • the antibody-SPIKE complex may comprise e.g., be attached, to an identifiable moiety.
  • the complex may be identified indirectly such as by using a secondary antibody.
  • diagnosis is corroborated using any diagnostic method known in the art, such as by measuring the viral load or titer, by antigen level measurement, antibody level measurement, virus isolation and/or genomic detection by reverse transcriptase- polymerase chain reaction (RT-PCR), etc.
  • RT-PCR reverse transcriptase- polymerase chain reaction
  • a higher viral load or titre often correlates with the severity of an active viral infection.
  • the quantity of virus per mF can be calculated for example by estimating the live amount of virus in an involved body fluid (e.g. serum sample or whole blood).
  • compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
  • a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
  • range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
  • a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
  • the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
  • method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
  • sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.
  • any Sequence Identification Number can refer to either a DNA sequence or a RNA sequence, depending on the context where that SEQ ID NO is mentioned, even if that SEQ ID NO is expressed only in a DNA sequence format or a RNA sequence format.
  • Antibody cloning was performed similarly to what was reported in [von Boehmer, L., Liu, C., Ackerman, S. et al. Sequencing and cloning of antigen- specific antibodies from mouse memory B cells. Nat Protoc 11, 1908-1923 (2016). www(dot)doi(dot)org/10(dot)1038/nprot(dot)2016(dot)102].
  • first round PCR products were used as a template for additional amplification with specific 5’ V and 3’ J primers containing restriction sites for subsequent cloning into Ig expression vectors containing the human Igyl constant region.
  • PCR products were purified (MACHEREY-NAGEL, 740609.250) and digested with the appropriate restriction enzymes - Agel and Sall for Igyl, Agel and BsiWI for IgK, Agel and Xhol for IgA. (NEB).
  • the digested products were purified before ligation into human Igyl, IgK and Ig/. expression vectors containing a murine Ig gene signal peptide sequence (accession no. DQ407610). Transcription is under the influence of the human cytomegalovirus (HCMV) promotor.
  • HCMV human cytomegalovirus
  • Ligation was performed in a total volume of 20 pl using T4 DNA Ligase (M0202L, NEB) and contained 7.5 pl of digested and purified PCR product and ⁇ 25 ng linearized vector. Competent E. Coli DH5aF bacteria (NEB) were transformed at 42 °C with 5 pl of the ligation product. Plasmid DNA was isolated from 2 ml bacteria cultures grown for 18-22 h at 37 °C in LB containing 100 pg/mL ampicillin. Colonies were screened by sequencing using 5' Absense primer (GCTTCGTTAGAACGCGGCTAC).
  • mAb vectors for IgGl heavy chain and Kappa or Lambda light chains were cotransfected at a ratio of 1:3 (H:K/L) into Expi293F cells (Thermo Fisher Scientific Inc.) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific Inc.). Seven days post transfection, the cell supernatant was collected, filtered (0.22 pm) and incubated with protein A coated agarose beads (GE Life Sciences, 17519901) for 2 h at RT. The beads were then loaded onto chromatography columns, washed, and eluted using 50 mM sodium phosphate (pH 3.0) into 1 M Tris-HCl (pH 8.0). Antibodies were buffer exchanged to PBS xl, aliquoted, and stored at -80 °C.
  • Pseudoparticles preparation and neutralization assays - were done as follows. SARS- CoV-2-Spike pseudoparticles were obtained by co-transfection of Expi293FTM cells with pCMV delta R8.2, pLenti-GFP (Genecopoeia), and pCDNA3.1 SAC19 according to manufacturer’s instructions (ThermoFisher Scientific) at a ratio of 1:2:1, respectively. The supernatant was harvested 72 hours post transfection, centrifuged at 1500 x g for 10 minutes to remove cell debris and passed through 0.45 pm filter (LIFEGENE, Israel).
  • pseudoparticles-containing supernatant was concentrated to 5 % of its original volume using Amicon Ultra with 100 KDa cutoff at 16°C (Merck Millipore).
  • HEK-293 cells stably expressing hACE2 were seeded into 0.1 % Gelatin-coated 96-well plates (Greiner) at an initial density of 0.75xl0 5 cells per well.
  • concentrated pseudoparticles with serial dilution of antibodies were incubated for 1 hour at 37 °C and then added to the 96 well pre-seeded plates.
  • IC50 was calculated by PRISM software fitting to a non-linear regression model.
  • Each PCR reaction contained 10 pL KAPA HiFi HotStart ReadyMix, 0.5 pM of each primer, 1 ng template DNA and the volumes were adjusted to 20 pL with DNase/RNase free water (Bio-Lab).
  • the PCR conditions were as follows: 95 °C for 3 min, 16 cycles of 98 °C for 20 sec and 72 °C for 90 sec. D ouble and triple amino acid mutants were generated similarly with appropriate template and primers.
  • Each construct was used to transiently transfect Expi293F cells (Thermo Fisher) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher). Seven days post transfection, the cell supernatant was collected, filtered (0.22 pm), and incubated with Ni 2+ -NTA agarose beads (GE Life Sciences) for 2 h at room temperature (RT). Proteins were eluted by 200 mM imidazole, buffer-exchanged to PBS xl, aliquoted and stored at -80 °C.
  • High-binding 96 well ELISA plates (Corning #9018) were coated with 1 pg/mL RBD in PBS xl overnight at 4 °C. The following day, the coating was discarded, the wells were washed with “washing buffer” containing PBS xl 0.05 % Tween20 and blocked for 2 h at RT with 200 pL of “blocking buffer” containing PBS xl 3% BSA (MP Biomedicals) 20 mM EDTA and 0.05% Tween20 (Sigma). Antibodies were added at a starting concentration of 4
  • the plates were then washed 3 times with washing buffer before adding a secondary anti-IgG (Jackson ImmmunoResearch) antibody conjugated to horseradish peroxidase (HRP) diluted 1:5000 in blocking buffer, and incubated for 1 h at RT. Following four additional washes, 100 pL of TMB (abeam) was added to each well and the absorbance at 650 nm was read after 20 min (BioTek 800 TS).
  • HRP horseradish peroxidase
  • Codon optimized sequences encoding the SARS-CoV-2 Alpha and Beta variants Spike proteins were downloaded from the NCBI data base, synthesized by Syntezza-Israel, and cloned into the pCMV3 mammalian expression vector. Each construct was individually used to transiently transfect Expi293F cells (Thermo Fisher Scientific Inc.) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific Inc.). 24 h post transfection the cells were centrifuged and resuspended in FACS buffer (PBS xl 2% FBS 2 mM EDTA).
  • ACE2:RBD inhibition ELISA high-binding 96 well plates were coated with 2 pg/ml human ACE2 in PBS xl overnight at 4 °C. The next day, plates were washed and blocked with blocking buffer for 2 hours at RT. Concurrently, biotinylated RBD was mixed with of 4-fold serial dilutions of plasma or mAbs. The RBD-plasma/mAb mix was then applied to the ACE2 coated plates and incubated for 30 min. Biotinylated RBD was detected via streptavidin conjugated to HRP (Jackson ImmmunoResearch 016-030-084).
  • Donors CoVOl and CoV02 were taken for further analysis. Twenty two monoclonal antibodies were produced from donors CoVOl and CoV02 (Table 2). Eight mAbs exhibited strong binding to SARS CoV-2 RBD ( Figure 4A and 4B). Amongst these mAbs only four mAbs, TAU- 1145, TAU-2189, TAU-2230 and TAU-2303, were able to inhibit RBD:ACE2 interaction in
  • Antibodies bind and neutralize SARS-CoV-02 variants
  • RBD was used as a probe to fish-out anti-RBD B cells and clone antibodies from two infected donors.
  • RBDs were produced from the emerging VOCs and tested for the binding of the mAbs by ELISA.
  • the majority of previously isolated anti-RBD mAbs demonstrated strong binding to VOC-RBDs ( Figure 9A); all mAbs bound to RBD from the alpha variant, five out of eight to Beta variant, seven out of eight to the Gamma variant (although some mAbs had weaker binding), and five out of eight to the Delta variants.
  • ACE2 binding site ACE2 binding site
  • TAU-1145 ACE2 binding site
  • -2189 -2189
  • -2230 -2303
  • -2303 ACE2 binding site
  • non-ACE2bs mAbs, TAU-1109, and TAU-2310 kept their binding to all variants, with similar affinity as to the original wild type strain.
  • E484K and L452R mutations reduce the binding of ACE2 mAbs, except TAU-2303 mAb
  • the present inventors expressed the Spike proteins of Alpha, Beta and Delta on HEK-293 cells and using flow cytometry assayed the ability of the mAbs to prevent the binding of ACE2-APC to the cells.
  • the present inventors observed increased binding to ACE2 of the Alpha, Beta and Delta Spikes over the W.T. Spike, aligning with previously published data that the affinity of these variants to hACE2 is much higher compared to W.T.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps humain comprenant un domaine de liaison à l'antigène qui se lie à un déterminant antigénique du coronavirus destiné à être utilisé dans la prévention, le traitement ou la détection d'une infection à coronavirus chez un sujet en ayant besoin, ledit domaine de liaison à l'antigène comprenant des régions déterminant la complémentarité (CDR) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 et CDRL3 ou la chaîne lourde et la chaîne légère d'un anticorps choisi dans le groupe figurant dans le tableau 5.
PCT/IL2021/051128 2020-09-14 2021-09-14 Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus Ceased WO2022054068A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077826P 2020-09-14 2020-09-14
US63/077,826 2020-09-14

Publications (1)

Publication Number Publication Date
WO2022054068A1 true WO2022054068A1 (fr) 2022-03-17

Family

ID=80630023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2021/051128 Ceased WO2022054068A1 (fr) 2020-09-14 2021-09-14 Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus

Country Status (1)

Country Link
WO (1) WO2022054068A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047459A2 (fr) * 2003-08-04 2005-05-26 University Of Massachusetts Acides nucleiques du sars, proteines, anticorps et utilisations associees
WO2005060520A2 (fr) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. Anticorps diriges contre sras-cov et methodes d'utilisation de ceux-ci
WO2006051091A1 (fr) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions contre le coronavirus du sras et utilisations de ces compositions
WO2007044695A2 (fr) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
WO2008060331A2 (fr) * 2006-05-19 2008-05-22 Amgen Inc. Anticorps au coronavirus sras
WO2009128963A2 (fr) * 2008-01-17 2009-10-22 Humab, Llc Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2015164865A1 (fr) * 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Anticorps neutralisant le coronavirus du syndrome respiratoire du moyen-orient et procédés d'utilisation de ceux-ci
WO2015179535A1 (fr) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
CN111620945A (zh) * 2020-05-09 2020-09-04 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种抗新型冠状病毒的单克隆抗体或其衍生体
WO2021045836A1 (fr) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-glycoprotéine spike du sars-cov 2 et fragments de liaison à l'antigène de ceux-ci
WO2021060837A1 (fr) * 2019-09-23 2021-04-01 Seoul National University R&Db Foundation Anticorps anti-mers-cov et son utilisation
WO2021173753A1 (fr) * 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Anticorps dirigés contre le sras-cov-2 et leurs procédés d'utilisation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047459A2 (fr) * 2003-08-04 2005-05-26 University Of Massachusetts Acides nucleiques du sars, proteines, anticorps et utilisations associees
WO2005060520A2 (fr) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. Anticorps diriges contre sras-cov et methodes d'utilisation de ceux-ci
WO2006051091A1 (fr) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions contre le coronavirus du sras et utilisations de ces compositions
WO2007044695A2 (fr) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
WO2008060331A2 (fr) * 2006-05-19 2008-05-22 Amgen Inc. Anticorps au coronavirus sras
WO2009128963A2 (fr) * 2008-01-17 2009-10-22 Humab, Llc Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2015164865A1 (fr) * 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Anticorps neutralisant le coronavirus du syndrome respiratoire du moyen-orient et procédés d'utilisation de ceux-ci
WO2015179535A1 (fr) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
WO2021060837A1 (fr) * 2019-09-23 2021-04-01 Seoul National University R&Db Foundation Anticorps anti-mers-cov et son utilisation
WO2021173753A1 (fr) * 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Anticorps dirigés contre le sras-cov-2 et leurs procédés d'utilisation
WO2021045836A1 (fr) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-glycoprotéine spike du sars-cov 2 et fragments de liaison à l'antigène de ceux-ci
CN111620945A (zh) * 2020-05-09 2020-09-04 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种抗新型冠状病毒的单克隆抗体或其衍生体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAROVICH MARY, MASCOLA JOHN R., COHEN MYRON S.: "Monoclonal Antibodies for Prevention and Treatment of COVID-19", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 324, no. 2, 14 July 2020 (2020-07-14), US , pages 131 - 132, XP055913549, ISSN: 0098-7484, DOI: 10.1001/jama.2020.10245 *

Similar Documents

Publication Publication Date Title
US11505597B2 (en) Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI896628B (zh) 針對嚴重急性呼吸症候群冠狀病毒２(SARS-CoV-2)之人單株抗體
He et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
CN108137676B (zh) gp120中和抗体及其用途
Pan et al. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
US20250145690A1 (en) Human monoclonal antibodies that broadly target coronaviruses
CA2982491C (fr) Neutralisation du virus du chikungunya a mediation par des anticorps
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20240182549A1 (en) Peptides and antibody fusions that bind to sars-cov-2 and methods of using same
WO2022054068A1 (fr) Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus
Liu et al. Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening
WO2025024717A2 (fr) Anticorps monoclonaux de sarbecovirus et leurs utilisations
WO2023039064A2 (fr) Anticorps largement neutralisants contre des virus de type sars
WO2023025813A1 (fr) Anticorps neutralisants dirigés contre la protéine de spicule du sras-cov-2
CN116867801A (zh) 与SARS-CoV-2刺突蛋白结合的单域抗体
Liu et al. Isolating multiple formats of human monoclonal neutralizing antibodies against
Martinez et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21866228

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21866228

Country of ref document: EP

Kind code of ref document: A1